Jiangsu Zenji Pharmaceuticals

Jiangsu Zenji Pharmaceuticals is a China-based pharmaceutical company specializing in the research, development, and manufacturing of innovative drugs, high-end pharmaceutical intermediates, and active pharmaceutical ingredients (APIs). The company maintains a strong focus on antiviral therapies, particularly for COVID-19, Hepatitis C, and HIV, as well as treatments for cardiovascular diseases and oncology. Zenji is notably recognized for developing Leritrelvir, a 3CL protease inhibitor approved in China for the treatment of COVID-19. With integrated R&D and GMP-compliant manufacturing capabilities, the company serves both domestic and international markets through its dual focus on proprietary drug discovery and high-quality chemical synthesis.